Guardant Health Earnings Call Transcripts
Fiscal Year 2026
-
Guardant360 and Reveal are driving growth through new clinical applications, including first-of-its-kind monitoring CDx and expanded MRD testing. Shield is rapidly closing the care gap in unscreened populations, supported by a growing sales force and strategic partnerships.
-
A major partnership with Quest Diagnostics is set to expand Shield test access and drive physician engagement, while updated CRC guidelines and ongoing R&D are fueling growth across the portfolio. Revenue and margin improvements are expected through operational efficiencies, sales force expansion, and targeted DTC campaigns.
-
Exceptional growth in 2025 is expected to continue in 2026, driven by innovation across Guardant360, Reveal, and SHIELD, with new applications, expanded sales force, and key partnerships fueling adoption. FDA approval and ACS guideline endorsement are anticipated catalysts for further volume and reimbursement gains.
-
The conference highlighted robust revenue and volume growth in oncology and screening, driven by smart platform innovation, new product launches, and strategic partnerships. Shield’s expansion into multi-cancer detection and strong financial position set the stage for continued growth and international expansion.
Fiscal Year 2025
-
Revenue grew 33% to $982M in 2025, driven by strong oncology and Shield screening adoption. 2026 guidance projects 27%–30% revenue growth, with continued investment in commercial expansion and new product launches.
-
Revenue is projected to reach $2.2 billion by 2028, led by oncology and expanding screening segments. Growth is fueled by product innovation, increased test utilization, and strategic partnerships, with a focus on margin improvement and operational efficiency. Breakeven is targeted by end of 2027.
-
Strong Q3 growth was driven by new product launches, high Shield adherence, and rapid salesforce expansion. Key 2026 catalysts include new therapy monitoring, FDA submissions, and expanded partnerships, with multi-cancer detection and Reveal Ultra set to drive future innovation.
-
The symposium addressed the urgent need for early cancer detection, rising healthcare costs, and access disparities. Industry leaders discussed advances in multi-cancer early detection, the importance of partnerships, and the economic and policy shifts required to integrate new diagnostics into healthcare.
-
Q3 2025 saw 39% revenue growth and record annualized revenue, with strong performance across oncology, biopharma, and screening. Shield and Reveal volumes accelerated, gross margins improved, and guidance for 2025 was raised. Cash flow breakeven is targeted by 2027.
-
A data-driven Smart Platform is accelerating innovation in cancer detection, therapy selection, and MRD, with Shield's CRC blood test achieving rapid adoption and expanding to multi-cancer detection. Financial targets were raised to $2.2B revenue by 2028, with breakeven moved up to Q4 2027 and major commercial partnerships and product launches fueling growth.
-
Significant progress was highlighted in screening, therapy selection, and MRD, with Shield gaining guideline inclusion and new partnerships expanding access. Product innovation, especially in smart liquid biopsy, is driving growth, while financial targets focus on margin expansion and cash flow break-even by 2028.
-
Q2 2025 saw robust revenue and volume growth, driven by innovation in liquid and tissue oncology testing. Shield's strong adoption and margin improvements are fueling expansion, while new AI-powered applications and multi-cancer detection initiatives are set to drive future growth.
-
Q2 2025 revenue grew 31% year-over-year, driven by strong oncology, biopharma, and screening performance. Gross margin improved to 66%, and full-year guidance was raised across revenue, Shield, and gross margin, with continued investment in commercial expansion.
-
The meeting was held virtually, with a quorum established and all proposals passed, including director elections, auditor ratification, and executive compensation approval. No questions were raised by stockholders during the Q&A session.
-
Accelerating growth across therapy selection, MRD, and screening platforms is driven by innovation, expanded reimbursement, and strong clinical data. Financial performance is improving with higher ASPs, gross margin gains, and a clear path to break-even by 2028.
-
FDA breakthrough designation and NCCN guideline support have accelerated Shield's adoption, while Guardant 360 and Reveal continue to expand with new applications and improved financial metrics. Commercial scaling and international projects, such as Abu Dhabi, are driving further growth.
-
Recent recognition and strong Q1 Shield test adoption led to raised annual guidance and revenue targets. Cost reductions have made Shield and Reveal gross margin positive, with further improvements expected. The integrated portfolio across screening, MRD, and therapy selection positions the company for leadership in the cancer care continuum.
-
Q1 2025 saw 21% revenue growth, driven by oncology and biopharma, with both Reveal and Shield achieving gross margin positivity. Full-year guidance was raised, reflecting strong volume growth, improved ASPs, and expanded coverage, while investments continue in commercial infrastructure.
-
ADLT status for Shield accelerates favorable Medicare pricing and commercial expansion, with ASP rising to $800 and volume guidance set at 45,000–55,000. Reveal achieves gross margin positivity and is poised for accelerated growth in 2025, with breast cancer as the next reimbursement target.
-
Medicare pricing for Shield was upgraded ahead of schedule, boosting ASP and enabling gross margin positivity from April. Expansion of the sales force and commercial infrastructure is planned, with Shield V2 and multicancer detection in development. Strong growth is also expected for Reveal and G360.
-
Management highlighted strong 2024 results, driven by Smart Liquid Biopsy upgrades, new biopharma deals, and Shield's FDA approval. 2025 growth is expected from expanded MRD reimbursement, new tissue tests, and a larger sales force, with profitability and multi-cancer expansion on track.
-
Strong 2024 growth was driven by product innovation, early achievement of ASP targets, and robust Shield launch. The company is expanding its platform, scaling commercial operations, and expects further margin improvements and new product launches in 2025.
Fiscal Year 2024
-
Record 2024 revenue growth was driven by strong clinical and biopharma performance, major product upgrades, and favorable reimbursement trends. 2025 guidance anticipates continued double-digit growth, with Shield and Reveal positioned for accelerated adoption and gross margin gains.
-
A $300 million legal win boosts credibility, while CGP and MRD markets show strong growth potential, driven by pharma partnerships, new product launches, and expanded reimbursement. Shield and Reveal are set for major milestones in 2025, with cost reductions and broader coverage expected.
-
Exceptional ASP growth and international expansion are driving strong performance, with new product launches and higher reimbursement rates supporting future growth. Shield and Reveal franchises are positioned for significant market share and profitability, with key milestones expected in 2025.
-
Strong Q3 growth and early Shield IVD success have driven confidence in surpassing long-term targets. Shield's first-mover advantage is expected to last 2.5 years, with regulatory and R&D milestones set for 2025. Reveal and therapy selection are on track for profitability and margin expansion.
-
Q3 2024 saw 34% revenue growth to $191.5M, driven by Guardant360 and biopharma strength. Shield launched as the first FDA-approved blood-based CRC screening test, with strong early demand and favorable Medicare pricing. Full-year guidance was raised, and oncology clinical volume growth is expected to accelerate in 2025.
-
Significant progress was highlighted in clinical adoption, product innovation, and financial performance, with strong growth in Guardant360 and Shield. Expansion into new markets, improved margins, and robust cash reserves position the company for continued growth and multi-cancer screening advancements.
-
Panelists discussed innovative cancer screening technologies, each targeting high-mortality cancers with distinct approaches and emphasizing the importance of regulatory approval, reimbursement, and robust clinical evidence. Adoption is driven by unmet needs, improved patient adherence, and strategic capital deployment.
-
Strong revenue growth was driven by clinical and biopharma volumes, with Shield's FDA approval and Medicare coverage marking a major milestone. The company is focused on expanding its product portfolio, achieving positive gross margins in 2025, and scaling sales with key milestones.
-
Q2 2024 revenue grew 29% year-over-year to $177.2M, driven by strong precision oncology and biopharma growth. Shield, the first FDA-approved blood test for CRC screening, launched with Medicare coverage, and 2024 revenue guidance was raised to $690–$700M.
-
FDA approved the Shield blood test as the first blood-based, first-line colorectal cancer screening for average-risk adults 45+, enabling broad Medicare coverage. The test offers a convenient alternative to colonoscopy and stool tests, with commercial launch and expanded sales force planned soon.
-
The meeting covered director elections, auditor ratification, and executive compensation, all of which passed by majority or plurality vote. No questions were submitted by stockholders, and final voting results will be filed with the SEC.
-
Strong Q3 results were driven by therapy selection and biopharma engagement, with Shield receiving a positive AdCom vote for first-line CRC screening. Operational efficiency, cost reductions, and international expansion are key growth drivers, while a robust cash position supports future innovation.
-
Board's review focused on executive compensation, not M&A. Strong Adcom support boosts optimism for FDA approval and a broad first-line label for CRC screening. Financial discipline is maintained with a $200M annual burn cap, and cost reductions plus positive gross margins are expected by 2025.
-
Strong Q1 growth and upgraded financial guidance reflect robust demand for precision oncology and liquid biopsy products. Regulatory milestones for the Shield blood test position it as a leader in non-invasive cancer screening, with expansion into multi-cancer detection planned.